Trial · NCT00753948
Exhaled Levels of Nitric Oxide
NCT00753948, Phase 2, Phase 3, Completed, VA Office of Research and Development; results first posted 2014-07-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Exhaled Levels of Nitric Oxide. Trials, record NCT00753948. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00753948
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Exhaled Levels of Nitric Oxide
- NCT number
- NCT00753948
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 23 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Tetraplegia, Asthma
- Interventions
- N-Nitro L-arginine-methylester (L-NAME)
- First posted
- 2008-09-17
- Last updated
- 2020-02-28
- Results first posted
- 2014-07-04
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Exhaled Levels of Nitric Oxide | Exhaled NO reported during visit, before intervention at baseline, post intervention at 60 minutes and 120 minutes | Nitric Oxide was measured applying a real time technique for measurement of Nitric Oxide in Exhaled Breath Condensate. Elevated Nitric Oxide in exhalate is a measure of elevated production of NO in conditions such as underlying inflammation and/or oxidative stress. Exhaled NO was reported as the mean of three values within 10% of each other. |
| Secondary | Specific Airway Conductance (sGaw) as Measured by Plethysmography | Specific airway conductance reported during visit, before intervention at baseline, post intervention at 60 minutes and 120 minutes | Specific airway conductance (sGaw) is the airway conductance relative to lung volume because it takes into account the important effect of lung volume on airway resistance, it is a useful index of bronchomotor tone. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Exhaled Levels of Nitric Oxide | Exhaled NO reported during visit, before intervention at baseline, post intervention at 60 minutes and 120 minutes | ppb (parts per bilion) | MEAN | |
| SECONDARY | Specific Airway Conductance (sGaw) as Measured by Plethysmography | Specific airway conductance reported during visit, before intervention at baseline, post intervention at 60 minutes and 120 minutes | L/sec/cmH20/L | MEAN |
Source ClinicalTrials.gov
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Exhaled Levels of Nitric Oxide | Chronic Tetraplegia | Baseline (before intervention) | 17.27 | Standard Deviation 4.96 | ppb (parts per bilion) |
| Exhaled Levels of Nitric Oxide | Mild Asthma | Baseline (before intervention) | 19.83 | Standard Deviation 8.15 | ppb (parts per bilion) |
| Exhaled Levels of Nitric Oxide | Healthy Controls | Baseline (before intervention) | 15.025 | Standard Deviation 9.75 | ppb (parts per bilion) |
| Exhaled Levels of Nitric Oxide | Chronic Tetraplegia | 60 minutes (post intervention) | 3.70 | Standard Deviation 3.14 | ppb (parts per bilion) |
| Exhaled Levels of Nitric Oxide | Mild Asthma | 60 minutes (post intervention) | 5.56 | Standard Deviation 2.93 | ppb (parts per bilion) |
| Exhaled Levels of Nitric Oxide | Healthy Controls | 60 minutes (post intervention) | 4.07 | Standard Deviation 3.47 | ppb (parts per bilion) |
| Exhaled Levels of Nitric Oxide | Chronic Tetraplegia | 120 minutes (post intervention) | 3.04 | Standard Deviation 2.23 | ppb (parts per bilion) |
| Exhaled Levels of Nitric Oxide | Mild Asthma | 120 minutes (post intervention) | 5.73 | Standard Deviation 3.70 | ppb (parts per bilion) |
| Exhaled Levels of Nitric Oxide | Healthy Controls | 120 minutes (post intervention) | 3.71 | Standard Deviation 3.46 | ppb (parts per bilion) |
| Specific Airway Conductance (sGaw) as Measured by Plethysmography | Chronic Tetraplegia | Baseline (before intervention) | 0.164 | Standard Deviation 0.071 | L/sec/cmH20/L |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Chronic Tetraplegia | 9 | |
| Overall Study | STARTED | Mild Asthma | 7 | |
| Overall Study | STARTED | Healthy Control | 7 | |
| Overall Study | COMPLETED | Chronic Tetraplegia | 9 | |
| Overall Study | COMPLETED | Mild Asthma | 7 | |
| Overall Study | COMPLETED | Healthy Control | 7 | |
| Overall Study | NOT COMPLETED | Chronic Tetraplegia | 0 | |
| Overall Study | NOT COMPLETED | Mild Asthma | 0 | |
| Overall Study | NOT COMPLETED | Healthy Control | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Chronic Tetraplegia | ||
| Total, all-cause mortality | Mild Asthma | ||
| Total, all-cause mortality | Healthy Control | ||
| Total, other adverse events | Chronic Tetraplegia | 0 | 9 |
| Total, other adverse events | Mild Asthma | 0 | 7 |
| Total, other adverse events | Healthy Control | 0 | 7 |
| Total, serious adverse events | Chronic Tetraplegia | 0 | 9 |
| Total, serious adverse events | Mild Asthma | 0 | 7 |
| Total, serious adverse events | Healthy Control | 0 | 7 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20012982 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00753948
GET https://conductscience.org/api/trials/v1/NCT00753948/registered